2025
3 November, 2025
FluoGuide A/S intends to carry out a directed share issue of approximately SEK 100 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA...
28 October, 2025
FluoGuide in advanced negotiations on collaboration agreement with a world leading medical technology company
Copenhagen, Denmark, 28 October 2025 – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company...
6 October, 2025
Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, presented at EANS
Copenhagen, Denmark, 6 October 2025 – FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech...
16 September, 2025
FluoGuide receives positive FDA feedback on FG001 in high-grade glioma
Copenhagen, Denmark, 16 September 2025 – FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback...
28 August, 2025
FluoGuide A/S publishes Interim Report H1 2025
Copenhagen, Denmark, 28 August 2025 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...
FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025. The following event will take place later that day...
Copenhagen, Denmark, 10 August 2025 – FluoGuide A/S is releasing a summary of its live-recorded interview at Redeye (English)...
31 July, 2025
Invitation: FluoGuide presentations on strategic collaborations and FG001 commercialization
FluoGuide is advancing its position in head and neck cancer treatment. On 21 July 2025, the company announced a strategic collaboration...
Copenhagen, Denmark, 21 July 2025 – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing...